ghk-cu fda approval status 2026 ghk cu peptide approved FDA restores non-injectable to 503A Category 1 — what it means for peptide compounding Regulatory Alert: FDA's April 2026
Description
TNX has more than 30 such repeats, so it has the potential to be quite flexible (22)
Formulated to deliver consistent results
By keeping the peptide in a desiccated, oxygen-free environment, its activity can be preserved until it is ready to be reconstituted for experimental use
It aligns with the "social salience" hypothesis, where oxytocin enhances attention to social cues and promotes approach behavior
